NCT02715089

Precise Treatment in Hepatobiliary Cancers (PTHBC)

Single Center, Single Arm, Open Study, to Explore and Evaluate the Precise Treatment in Hepatobiliary Cancers(PTHBC)

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 30 (estimated)
• Sponsor: Peking Union Medical College Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to explore the precise treatment in hepatobiliary cancer patients and evaluate drug safety, progression free and overall survival. This trial study is based on genetic tests, then therapeutic target drugs are administered according to the genetic test reports. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit from precise treatment which targets particular genetic abnormality. The identifications of these genetic abnormalities may help treat hepatobiliary cancer patients better.

Detailed description

The genetic tests are performed for the eligible subjects in this study, then therapeutic target drugs are administered according to the genetic test reports. While the precise treatments, follow-ups are conducted to evaluate the efficacy and safety of the target drugs for the subjects, until the overall survival. Study Type: Non-Interventional. Masking: Open Label.

Conditions

• Liver Neoplasms
• Biliary Tract Neoplasms
• Hepatobiliary Neoplasms

Interventions

Type	Name	Description
GENETIC	Precise treatment	During screening stage, all patients should accept next-generation sequencing (NGS) test.

Timeline

• Start date: 2015-12-01
• Primary completion: 2017-12-01
• Completion: 2018-12-01
• First posted: 2016-03-22
• Last updated: 2016-03-22

Locations

1 site across 1 country: China